Euro Foscan study to boost biolitec's PDT (photodynamic therapy) drug
This article was originally published in Clinica
German photodynamic therapy company biolitec last week successfully ended a five-year-plus study of its Foscan PDT light-activated drug for head and neck tumours, which was required by the European Medicines Evaluation Agency (EMEA). Jena-based biolitec says the therapy should now be able to retain its approval. Furthermore, completion of the study will lead to "considerably greater" market penetration for the photodynamic therapy (PDT) drug, for which the company is now also preparing to embark on approval negotiations with the US FDA.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.